Mechanisms of <italic style="font-style: italic">Compound Huangdai Tablet </italic>Formulation in reversing arsenic resistance in mice with acute promyelocytic leukemia

XUE Chengyuan; CUI Meichen; WEN Xu; LIAO Jinglin; Qi Yubo; SI Yuping; YANG Qianru; HAN Xinpu; LIU Kexin; HOU Li

doi:10.16025/j.1674-1307.2025.07.002

您当前的位置：

首页 >

文章列表页 >

Mechanisms of Compound Huangdai Tablet Formulation in reversing arsenic resistance in mice with acute promyelocytic leukemia

更新时间：2025-09-11

- Mechanisms of Compound Huangdai Tablet Formulation in reversing arsenic resistance in mice with acute promyelocytic leukemia
- Beijing Journal of Traditional Chinese Medicine Vol. 44, Issue 7, Pages: 820-826(2025)
- 作者机构：
  
  北京中医药大学东直门医院血液肿瘤科，北京 100700
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2025.07.002
  CLC：
- Received：25 April 2025，
  
  Published：25 July 2025
- 稿件说明：
移动端阅览
薛程元，崔美晨，文旭，等.复方黄黛片组方配伍逆转急性早幼粒细胞白血病小鼠砷剂耐药的机制研究［J］.北京中医药，2025，44（7）：820-826.

XUE Chengyuan,CUI Meichen,WEN Xu,et al.Mechanisms of Compound Huangdai Tablet Formulation in reversing arsenic resistance in mice with acute promyelocytic leukemia[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(07):820-826.
薛程元，崔美晨，文旭，等.复方黄黛片组方配伍逆转急性早幼粒细胞白血病小鼠砷剂耐药的机制研究［J］.北京中医药，2025，44（7）：820-826. DOI： 10.16025/j.1674-1307.2025.07.002.

XUE Chengyuan,CUI Meichen,WEN Xu,et al.Mechanisms of Compound Huangdai Tablet Formulation in reversing arsenic resistance in mice with acute promyelocytic leukemia[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(07):820-826. DOI： 10.16025/j.1674-1307.2025.07.002.

摘要

目的

明确复方黄黛片组方对HL-60-早幼粒细胞白血病（PML）

A216V

-维甲酸受体α（RARα）荷瘤小鼠的抗肿瘤效应和逆转砷剂耐药作用机制。

方法

用耐砷HL-60-PML

A216V

-RARα细胞，构建裸鼠移植瘤模型，成模后随机分为模型组、雄黄组、三药（青黛、太子参、丹参）联合组、四药（雄黄、青黛、太子参、丹参）联合组，各5只，分别予生理盐水及各药物饮片水煎剂灌胃，期间记录大鼠体质量变化，测量瘤体体积，2周后取材肿瘤组织。HE染色观察病理形态，TUNEL染色检测细胞凋亡情况，免疫组化检测Ki67表达情况，流式细胞术检测CD33及CD11b表达情况。

结果

三药联合组、四药联合组瘤体体积均小于模型组、雄黄组（

0.01）；雄黄组瘤体体积小于模型组，差异无统计学意义（

0.05）。三药联合组、四药联合组与雄黄组瘤体质量比较，差异无统计学意义（

0.05）。抑瘤率：雄黄组21.93%，三药联合组37.77%，四药联合组43.60%。雄黄组肿瘤细胞排列相对松散，细胞周边呈圆环状空隙；三药联合组肿瘤组织结构明显松散，伴有大量脂肪空泡；四药联合组肿瘤组织结构较杂乱，伴有大量脂肪空泡。与雄黄组比较，三药联合组肿瘤细胞凋亡率低（

0.01），四药联合组肿瘤细胞凋亡率高（

0.01）；与三药联合组比较，四药联合组肿瘤细胞凋亡率高（

0.01）。与雄黄组比较，三药联合组肿瘤组织中Ki-67阳性细胞比例高（

0.01）；与三药联合组比较，四药联合组肿瘤组织中Ki-67阳性细胞比例低（

0.01）。与雄黄组比较，三药联合组CD33表达低（

0.01）；与三药联合组比较，四药联合组CD33表达高（

0.01）。与雄黄组比较，三药联合组CD11b表达呈下降趋势，但差异无统计学意义（

0.05）；四药联合组CD11b表达高（

0.01）；三药联合组与四药联合组间差异亦有统计学意义（

0.01）。

结论

复方黄黛片组方配伍对耐砷急性早幼粒细胞白血病（APL）细胞具有促凋亡、诱导分化，抑制细胞增殖的作用，可逆转砷剂耐药。

Abstract

Objective

To clarify the antitumor effects and mechanisms of Compound Huangdai Tablet formulation in reversing arsenic resistance in HL-60-promyelocytic leukemia （PML）

A216V

-retinoic acid receptor α （RARα） tumor-bearing mice.

Methods

A xenograft model was established in nude mice using arsenic-resistant HL-60-PML

A216V

-RARα cells. After model establishment， the mice were rand

omly divided into model group， realgar group， three-drug combination group， and four-drug combination group， with five mice in each group. Mice were gavaged with normal saline or water decoctions of the corresponding drugs. Body weight and tumor volume were recorded during the experiment， and tumor tissues were collected after 2 weeks. Pathological morphology was observed by HE staining， apoptosis was detected by TUNEL assay， Ki-67 expression was assessed by immunohistochemistry， and CD33 and CD11b expression levels were measured by flow cytometry.

Results

Tumor volumes in the three-drug and four-drug combination groups were significantly smaller than those in the model and realgar groups （

0.01）. Tumor volume in the realgar group was lower than that in the model group， but the difference was not statistically significant （

0.05）. Tumor weights in the three-drug and four-drug groups did not differ significantly from that in the realgar group （

0.05）. Tumor inhibition rates were 21.93% in the realgar group， 37.77% in the three-drug group， and 43.60% in the four-drug group. Histologically， tumors in the realgar group showed relatively loose cell arrangement with pericellular vacuoles； the three-drug group exhibited markedly loose structures with abundant fat vacuoles； the four-drug group displayed more disorganized structures with abundant fat vacuoles. Compared with the realgar group， the apoptosis rate was lower in the three-drug group （

0.01） and higher in the four-drug group （

0.01）. Compared with the three-drug group， the apoptosis rate in the four-drug group was also higher （

0.01）. The proportion of Ki-67 positive cells was higher in the three-drug group than in the realgar group （

0.01）， and lower in the four-drug group than in the three-drug group （

0.01）. Compared with the realgar group， CD33 expression was re

duced in the three-drug group （

0.01） but elevated in the four-drug group relative to the three-drug group （

0.01）. CD11b expression showed a downward trend in the three-drug group compared with the realgar group， though not statistically significant （

0.05）， while it was significantly increased in the four-drug group （

0.01）， with a significant difference also observed between the three- and four-drug groups （

0.01）.

Conclusion

The

Compound Huangdai Tablet

formulation exerts pro-apoptotic and differentiation-inducing effects， and inhibits proliferation in arsenic-resistant acute promyelocytic leukemia （APL） cells， thereby contributing to the reversal of arsenic resistance.

关键词

Keywords

references

杨茜茹 , 田劭丹 , 薛程元 , 等 . 复方浙贝颗粒基于MDM2/p53信号通路调节MHC-Ⅱ逆转白血病多药耐药机制研究 [J ] . 北京中医药 , 2025 , 44 ( 3 ): 325 - 330 .

IYER SG , ELIAS L , STANCHINA M , et al . The treatment of acute promyelocytic leukemia in 2023:paradigm,advances,and future directions [J ] . Front Oncol , 2022 , 12 : 1062524 .

李慧 , 庄海峰 . 中医辨治急性白血病的理论集萃 [J ] . 浙江中西医结合杂志 , 2021 , 31 ( 5 ): 478 - 479,494 .

HUANG DP , YANG LC , CHEN YQ , et al . Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group [J ] . Blood Cancer J , 2023 , 13 ( 1 ): 178 .

ZHU HH , WU DP , DU X , et al . Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia:a non-inferiority,randomised phase 3 trial [J ] . Lancet Oncol , 2018 , 19 ( 7 ): 871 - 879 .

HUANG Q , WANG T , XIONG Y , et al . Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms [J ] . Chin Herb Med , 2022 , 14 ( 1 ): 154 - 165 .

LI R , XUE C , PAN Y , et al . Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway [J ] . J Ethnopharmacol , 2024 , 326 : 117778 .

LIU Y , LYU G , BAI J , et al . Effects of HMGA2 on the epithelial-mesenchymal transition-related genes in ACHN renal cell carcinoma cells-derived xenografts in nude mice [J ] . BMC Cancer , 2022 , 22 ( 1 ): 421 .

LUO S , TIAN J , SUN X , et al . Oral realgar-indigo naturalis formula treatment for acute promyelocytic leukemia in children:a randomized, control clinical trial [J ] . Evid Based Complement Alternat Med , 2022 : 8314176 .

CHEN Y , LI M , WU H , et al . Arsenic trioxide induces proteasome dependent TBLR1-RARα degradation to improve leukemia eradication through cell differentiation enhancement [J ] . J Cancer , 2022 , 13 ( 7 ): 2301 - 2311 .

TESTA U , PELOSI E . Function of PML-RARA in acute promyelocytic leukemia [J ] . Adv Exp Med Biol , 2024 , 1459 : 321 - 339 .

PEDDI K , WIGGINS B , CHOUDHURY O , et al . Intracranial hemorrhage secondary to newly diagnosed acute promyelocytic leukemia:a cautionary tale [J ] . Cureus , 2022 , 14 ( 3 ): e23252 .

SONG X , HU X , LYU S , et al . Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia [J ] . Eur J Haematol , 2014 , 93 ( 1 ): 54 - 62 .

BALASUNDARAM N , GANESAN S , CHENDAMARAI E , et al . Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia [J ] . Blood Adv , 2022 , 6 ( 2 ): 652 - 663 .

刘海英 , 司文涛 , 李育林 , 等 . 中医药治疗骨髓增生异常综合征的现状及机制研究进展 [J ] . 北京中医药 , 2025 , 44 ( 2 ): 246 - 252 .

LOU Y , MA Y , JIN J , et al . Oral realgar-indigo naturalis formula plus retinoic acid for acute promyelocytic leukemia [J ] . Front Oncol , 2020 , 10 : 597601 .

WANG L , ZHOU GB , LIU P , et al . Dissection of mechanisms of Chinese medicinal formula realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia [J ] . Proc Natl Acad Sci USA , 2008 , 105 ( 12 ): 4826 - 4831 .

PU Y , ZHU J , XU J , et al . Antitumor effect of a polysaccharide from pseudostellaria heterophylla through reversing tumor-associated macrophages phenotype [J ] . Int J Biol Macromol , 2022 , 220 : 816 - 826 .

李蕊白 , 潘一鸣 , 刘宇 , 等 . 靛玉红及丹参酮Ⅱa促进雄黄降解突变型PMLA216T-RARα的作用机制研究 [J ] . 北京中医药 , 2021 , 40 ( 5 ): 461 - 465 .

CLARK MC , STEIN A . CD33 directed bispecific antibodies in acute myeloid leukemia [J ] . Best Pract Res Clin Haematol , 2020 , 33 ( 4 ): 101224 .

XU S , LI X , ZHANG J , et al . Prognostic value of cd11b expression level for acute myeloid leukemia patients: a meta-analysis [J ] . PLoS One , 2015 , 10 ( 8 ): e0135981 .

LIU X , HOGG GD , ZUO C , et al . Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity [J ] . Cancer Cell , 2023 , 41 ( 6 ): 1073 - 1090, e 12 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰

Mechanisms of Compound Huangdai Tablet Formulation in reversing arsenic resistance in mice with acute promyelocytic leukemia

DOI：10.16025/j.1674-1307.2025.07.002

摘要

Abstract

关键词

Keywords

references